Literature DB >> 10501234

Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif.

F Brown1, N Benkirane, D Limal, H Halimi, J F Newman, M H Van Regenmortel, J P Briand, S Muller.   

Abstract

The major immunogenic site of foot-and-mouth disease virus (FMDV) is contained in a disordered loop comprising residues 134-158 of capsid protein VP1, located on the surface of the viral particle. Peptides corresponding to this sequence generally elicit protective levels of neutralizing antibodies in guinea pigs. In some instances, however, the level of neutralizing antibodies is low although the level of antibodies against the peptide, determined by ELISA, is as high as that in the sera with high neutralizing antibody titres. In an attempt to ascertain the reason for this difference, we have synthesized on a cellulose membrane 10 overlapping decapeptides, offset by one residue, covering the segment 141-159 of VP1 of two viruses belonging to serotypes A12 and O1, and tested them with guinea pig antisera raised against peptide 141-159, VP1 and FMDV particles (SPOTscan method). With type A, some peptides which were strongly positive with highly neutralizing antisera did not include the RGD triplet located at residues 145-147. In contrast, antisera with low neutralization titres reacted only with decapeptides which included the RGD motif. Moreover, peptide 147-156 coupled to keyhole limpet haemocyanin, but not peptide 141-149 coupled to the same carrier, elicited high levels of neutralizing antibodies in guinea pigs. In the case of serotype O, highly neutralizing antisera to virus reacted in ELISA with peptides 141-150 (containing the RGD motif) and 135-144 (located upstream from the RGD motif). The results suggest that the RGD triplet is not an indispensable constituent of peptides able to elicit a neutralizing antibody response against the virus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501234     DOI: 10.1016/s0264-410x(99)00169-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Cellular DNAJA3, a Novel VP1-Interacting Protein, Inhibits Foot-and-Mouth Disease Virus Replication by Inducing Lysosomal Degradation of VP1 and Attenuating Its Antagonistic Role in the Beta Interferon Signaling Pathway.

Authors:  Wei Zhang; Fan Yang; Zixiang Zhu; Yang Yang; Zhifang Wang; Weijun Cao; Wen Dang; Linlin Li; Ruoqing Mao; Yongjie Liu; Hong Tian; Keshan Zhang; Xiangtao Liu; Junwu Ma; Haixue Zheng
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

2.  Xenoepitope substitution avoids deceptive imprinting and broadens the immune response to foot-and-mouth disease virus.

Authors:  Steven M Szczepanek; Roger W Barrette; Debra Rood; Diana Alejo; Lawrence K Silbart
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

3.  Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus.

Authors:  Huiying Fan; Tiezhu Tong; Huanchun Chen; Aizhen Guo
Journal:  Virus Genes       Date:  2007-05-12       Impact factor: 2.332

4.  Isolation, identification and complete genome sequence analysis of a strain of foot-and-mouth disease virus serotype Asia1 from pigs in southwest of China.

Authors:  Xin Yang; Ying-Shun Zhou; Hong-Ning Wang; Yi Zhang; Kun Wei; Ting Wang
Journal:  Virol J       Date:  2011-04-16       Impact factor: 4.099

5.  Comparative studies of the capsid precursor polypeptide P1 and the capsid protein VP1 cDNA vectors for DNA vaccination against foot-and-mouth disease virus.

Authors:  Ning-Sun Yang; Jeng-Hwan Wang; Ku-Feng Lin; Chien-Yu Wang; Suk-Am Kim; Yu-Ling Yang; Ming-Hwa Jong; Tsun-Yung Kuo; Shiow-Suey Lai; R Holland Cheng; Ming-Tsair Chan; Shu-Mei Liang
Journal:  J Gene Med       Date:  2005-06       Impact factor: 4.565

6.  Examination of soluble integrin resistant mutants of foot-and-mouth disease virus.

Authors:  Paul Lawrence; Michael LaRocco; Barry Baxt; Elizabeth Rieder
Journal:  Virol J       Date:  2013-01-02       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.